CY1125285T1 - Θεραπεια για τη νοσο του παρκινσον - Google Patents

Θεραπεια για τη νοσο του παρκινσον

Info

Publication number
CY1125285T1
CY1125285T1 CY20221100369T CY221100369T CY1125285T1 CY 1125285 T1 CY1125285 T1 CY 1125285T1 CY 20221100369 T CY20221100369 T CY 20221100369T CY 221100369 T CY221100369 T CY 221100369T CY 1125285 T1 CY1125285 T1 CY 1125285T1
Authority
CY
Cyprus
Prior art keywords
3haloalkyl
3alkyl
hydrogen
disease
parkinson
Prior art date
Application number
CY20221100369T
Other languages
Greek (el)
English (en)
Inventor
Sanjay Nandlalji MANDHANE
Manoj Atmaramji UPADHYA
Sameer Vishwanath MEHETRE
Gajanan Uttamrao CHIDREWAR
Prabal Sengupta
Trinadha Rao Chitturi
Nitin Krishnaji Damle
Original Assignee
Sun Pharma Advanced Research Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Limited filed Critical Sun Pharma Advanced Research Company Limited
Publication of CY1125285T1 publication Critical patent/CY1125285T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20221100369T 2016-06-02 2022-05-27 Θεραπεια για τη νοσο του παρκινσον CY1125285T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02

Publications (1)

Publication Number Publication Date
CY1125285T1 true CY1125285T1 (el) 2025-03-28

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100369T CY1125285T1 (el) 2016-06-02 2022-05-27 Θεραπεια για τη νοσο του παρκινσον

Country Status (26)

Country Link
US (4) US10849887B2 (Direct)
EP (2) EP4085912A1 (Direct)
JP (1) JP6974357B2 (Direct)
KR (1) KR102508288B1 (Direct)
CN (1) CN109475539B (Direct)
AU (1) AU2017273415B2 (Direct)
CL (1) CL2018003431A1 (Direct)
CY (1) CY1125285T1 (Direct)
DK (1) DK3463351T3 (Direct)
ES (1) ES2914782T3 (Direct)
HR (1) HRP20220683T1 (Direct)
HU (1) HUE059387T2 (Direct)
IL (1) IL263188B (Direct)
LT (1) LT3463351T (Direct)
MX (1) MX385276B (Direct)
MY (1) MY193754A (Direct)
NZ (1) NZ748592A (Direct)
PH (1) PH12018502457B1 (Direct)
PL (1) PL3463351T3 (Direct)
PT (1) PT3463351T (Direct)
RS (1) RS63243B1 (Direct)
SG (1) SG11201810294QA (Direct)
SI (1) SI3463351T1 (Direct)
SM (1) SMT202200228T1 (Direct)
UA (1) UA123018C2 (Direct)
WO (1) WO2017208267A1 (Direct)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
EP4085912A1 (en) 2016-06-02 2022-11-09 Sun Pharma Advanced Research Company Limited Treatment for parkinson s disease
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
WO2020106825A1 (en) 2018-11-20 2020-05-28 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
EA202193211A1 (ru) * 2019-06-11 2022-03-30 Сан Фарма Эдванст Рисерч Компани Лтд. Лечение синуклеопатий
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
WO2022024072A1 (en) 2020-07-31 2022-02-03 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
CA3251516A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Methods of reducing progression of neurodegenerative disease
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608829T3 (es) * 2011-01-21 2017-04-17 Sun Pharma Advanced Research Company Limited Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
CA2985161A1 (en) * 2015-05-18 2016-11-24 Sun Pharma Advanced Research Company Limited Novel amidoheteroaryl aroyl hydrazide ethynes
EP4085912A1 (en) * 2016-06-02 2022-11-09 Sun Pharma Advanced Research Company Limited Treatment for parkinson s disease

Also Published As

Publication number Publication date
RS63243B1 (sr) 2022-06-30
SMT202200228T1 (it) 2022-07-21
HUE059387T2 (hu) 2022-11-28
IL263188A (en) 2018-12-31
US11583522B2 (en) 2023-02-21
PH12018502457B1 (en) 2022-01-12
US11813252B2 (en) 2023-11-14
MY193754A (en) 2022-10-27
BR112018074439A2 (pt) 2019-03-06
PL3463351T3 (pl) 2022-06-20
EP3463351A1 (en) 2019-04-10
JP2019520344A (ja) 2019-07-18
ES2914782T3 (es) 2022-06-16
AU2017273415A1 (en) 2018-12-06
AU2017273415B2 (en) 2023-01-19
MX385276B (es) 2025-03-18
SI3463351T1 (sl) 2022-07-29
US20190275017A1 (en) 2019-09-12
CN109475539B (zh) 2021-12-28
HRP20220683T1 (hr) 2022-07-08
WO2017208267A1 (en) 2017-12-07
DK3463351T3 (da) 2022-06-07
IL263188B (en) 2021-08-31
CL2018003431A1 (es) 2019-05-10
KR20190015257A (ko) 2019-02-13
CA3024976A1 (en) 2017-12-07
US20240066014A1 (en) 2024-02-29
NZ748592A (en) 2025-11-28
JP6974357B2 (ja) 2021-12-01
US20210015805A1 (en) 2021-01-21
UA123018C2 (uk) 2021-02-03
KR102508288B1 (ko) 2023-03-09
CN109475539A (zh) 2019-03-15
US10849887B2 (en) 2020-12-01
PT3463351T (pt) 2022-06-02
EP4085912A1 (en) 2022-11-09
EP3463351B1 (en) 2022-04-27
SG11201810294QA (en) 2018-12-28
MX2018014944A (es) 2019-03-07
PH12018502457A1 (en) 2019-10-21
US20220273632A1 (en) 2022-09-01
LT3463351T (lt) 2022-06-10

Similar Documents

Publication Publication Date Title
CY1125285T1 (el) Θεραπεια για τη νοσο του παρκινσον
CY1125178T1 (el) Διεγερτες της sgc
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1124489T1 (el) Αναστολεις της hpk1 και μεθοδοι χρησης αυτων
CY1125051T1 (el) Συντηγμενη ενωση αναστολεα jak ιμιδαζο-πιπεριδινης
CY1123186T1 (el) Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124112T1 (el) Νευροδραστικα στεροειδη, συνθεσεις, και χρησεις αυτων
CY1121901T1 (el) Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων
CY1125963T1 (el) Ρυθμιστες υποδοχεα ρ2χ3 και ρ2χ2/3 διαμινοπυριμιδινης για χρηση στη θεραπεια βηχα
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1124929T1 (el) 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139
CY1126082T1 (el) Τροποποιητες toy trex1
CY1119642T1 (el) Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CR20190124A (es) Inhibidores de ssao de aminopirimidina
CY1123154T1 (el) Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου
CY1120111T1 (el) Αντιβακτηριακα παραγωγα 2η-ινδαζολης
CY1120836T1 (el) Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
CY1121362T1 (el) Παραγωγα της 1,2-διϋδρο-3η- πυρρολo[1,2-c] ιμιδαζολ-3-ονης και η χρηση τους ως αντιβακτηριακοι παραγοντες
CY1123582T1 (el) Προφαρμακα των αναστολεων αντιστροφης μεταγραφασης hiv